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Although the role of the retinoblastoma protein 
(pRB) in cell cycle control has been extensively studied, 
druggable targets downstream of pRB remain to be 
identified. Retinoblastoma is the most common childhood 
intraocular malignancy caused by bi-allelic inactivation 
of the retinoblastoma gene (RB1). Despite recent progress 
in clinical outcomes of retinoblastoma, enucleation (eye 
removal) remains a frequent treatment for retinoblastoma 
and the survival rate for metastatic retinoblastoma is 
just over 10%. Thus, there is a pressing clinical need to 
determine the factors responsible for tumor progression 
following RB1 inactivation in order to facilitate the 
development of new therapeutic strategies. Furthermore, 
the loss of pRB function contributes to a wide array of 
human cancers. A few years ago, we elucidated how 
tumors progress quickly following RB1 inactivation, 
showing that while the retinoblastoma genome is stable 
– with RB1 being the only known tumor suppressor gene 
mutated – multiple cancer pathways can be deregulated 
epigenetically [1].
HELLS (helicase, lymphoid specific; also known 
as LSH, ICF4, PASG, and SMARCA6) belongs to the 
SNF2 family of chromatin-remodeling ATPases. It 
remodels chromatin to allow accessibility of DNMT3A 
or DNMT3B to DNA in order to support de novo DNA 
methylation and stable gene silencing during cellular 
differentiation [2]. We have previously identified that 
upregulation of HELLS following RB1 inactivation could 
cause the epigenetic gene expression deregulation that 
results in tumorigenesis [3]. HELLS has an interesting 
connection to the RB/E2F pathway: the HELLS gene is 
a direct target of E2F1 [4] and HELLS protein interacts 
with E2F3 at several E2F target genes that control 
cell cycle entry [5,6]. Similar to what we observed in 
retinoblastoma, depletion of HELLS in glioblastoma and 
several carcinomas impairs tumor growth, suggesting 
that HELLS may contribute to the malignant progression 
of various tumors. We have also reported that HELLS is 
overexpressed in osteosarcoma; however, we found no 
evidence of HELLS serving as a driver of malignancy 
in these tumors [7]. The osteosarcoma study offered a 
precautionary perspective indicating that while HELLS 
level may reflect RB/E2F pathway inactivation, its 
upregulation may not always be synonymous with a 
critical role in tumor formation or tumor maintenance 
across all malignancies, and therefore should not be a 
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Figure 1: Model for HELLS function as driver of tumorigenesis in the developing retina. In the absence of the RB family (RB 
and p107), E2F1 drives Hells transcription, causing HELLS overexpression. HELLS protein can then function as an E2F3 transcriptional 
co-activator, resulting in the expression of several genes that stimulate G1/S-transition and cell proliferation that promote retinoblastoma.
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warranted target for therapeutics against tumors in which 
HELLS overexpression is observed [7].
In our latest study, we examined the role of 
HELLS in normal retina development and tumorigenesis 
using novel Hells conditional knockout mouse models. 
Unlike previous reports showing impaired self-renewal 
and maintenance in neural progenitor cells during 
development [8], our results indicated that Hells-null 
retinal progenitor cells (RPCs) divide, undergo cell-fate 
specification, and give rise to normally laminated and 
fully functional retinae. In spite of the dispensable role 
of HELLS during retinal development, genetic ablation 
of Hells in a genetically engineered mouse model of 
retinoblastoma led to a drastic increase in survival and 
decrease in morbidity compared to littermate controls 
[6]. Intriguingly, despite the role of HELLS in facultative 
heterochromatin formation, we found no global alterations 
in DNA methylation and only mild changes in chromatin 
structure variations upon Hells genetic ablation in the 
retinoblastoma-prone retina and tumors. Transcriptomic 
analyses did reveal a significant downregulation in the 
expression of cell cycle genes upon Hells genetic ablation. 
Interestingly, loss of Hells did not alter proliferation in 
retinal progenitor cells – as reflected by the normal 
functioning Hells-null retina –, yet drastically reduced 
cellular proliferation in the RB-null retina (i.e. initiated 
cells). The observations in this study have a remarkable 
similarity with those on the E2F family. Activator E2Fs, 
particularly E2F1 and E2F3, control the transcription of 
genes required for DNA replication and proliferation of 
quiescent cells but are not required for normal progenitor 
division in several tissues, including the developing 
retina [9]. However, activator E2Fs are essential for 
ectopic proliferation in differentiating RB-null cells 
such that removing E2F1 or E2F3 completely block 
retinoblastoma formation [3,10,11]. Thus, HELLS appear 
to be a critical effector of the E2F-dependent ectopic 
proliferation observed in the RB-null retina. We propose 
that in the absence of the RB family, the resulting E2F1 
transcriptional derepression drives the expression of 
Hells. Consequently, HELLS can act as a transcriptional 
co-activator of E2F3 (also transcriptionally derepressed 
in the absence of RB), stimulating the expression of pro-
proliferative genes (e.g. Pcna, E2f1, Cdc6 and Mcm4) and 
retinoblastoma formation (Figure 1).
Many limitations still exist when utilizing current 
methods for the treatment of retinoblastoma. The 
significant increase in survival observed in Hells knockout 
mouse models of retinoblastoma make HELLS an 
interesting candidate for the treatment of retinoblastoma. 
HELLS is nonessential for retina development and its 
expression is absent in fully differentiated retina. These 
unique characteristics may open up a new avenue for 
the ocular delivery of HELLS inhibitors which holds 
potential in reducing tumor burden with low risk of 
retinal toxicities.
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